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There is uncertainty about the risk of developing non-
melanoma skin cancer (NMSC), including basal cell 
carcinoma and squamous cell carcinoma (SCC), in pa-
tients with atopic dermatitis (AD) treated with oral im-
munosuppressive drugs. A total of 557 patients with 
AD treated with these drugs in the University Medi-
cal Center Utrecht and Groningen, the Netherlands, 
were analysed. NMSC after oral immunosuppres-
sive treatment was reported in 18 patients (3.2%). 
The standardized incidence ratio for developing SCC 
was 13.1 (95% confidence interval (CI) 6.5–19.7). 
Patients developing NMSC were older at the start of 
therapy (p < 0.001) and data lock (p < 0.001) compa-
red with patients without NMSC. No significant diffe-
rences were found in sex, cumulative days of oral im-
munosuppressive drugs and follow-up between these 
groups (p = 0.42, p = 0.88, and p = 0.34, respectively). 
In interpreting these results it is important to inclu-
de other factors, such as lack of association between 
treatment duration and tumour development and the 
long interval between treatment discontinuation and 
tumour development in some patients.
Key words: atopic dermatitis; oral immunosuppressive drugs; 
non-melanoma skin cancer.
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Atopic dermatitis (AD) is a chronic inflammatory skin disease with a prevalence of 1–3% in adults (1). 
Although AD can be controlled adequately with topical 
treatment and/or ultraviolet (UV) light therapy in the 
majority of patients, a subgroup of severe and difficult-
to-treat patients remains. Furthermore, in some patients 
it is impossible to taper topical corticosteroid treatment 
to a safe maintenance scheme. Oral immunosuppressive 
drugs are indicated in all of these patients. 
Oral immunosuppressive drugs that are regularly used 
in the management of AD are cyclosporin A (CsA), aza-
thioprine (AZA), methotrexate (MTX), mycophenolate 
mofetil (MMF), enteric-coated mycophenolate sodium 
(EC-MPS), (extended-release) tacrolimus and systemic 
glucocorticosteroids. 
Clinical efficacy and safety have been proven in 
clinical trials for most of these drugs (2–5). However, 
treatment duration in clinical trials is limited. Due to 
the chronic nature of AD, long-term treatment with oral 
immunosuppressive drugs is often necessary to maintain 
adequate disease control. Recent drug survival studies 
demonstrate that oral immunosuppressive drugs are 
regularly used for many years in daily practice (6–8).
An important barrier to long-term use of oral immuno-
suppressive drugs in patients with AD is the possible in-
creased risk of development of malignancies, especially 
non-melanoma skin cancer (NMSC), including basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC). 
Most data on the risk of developing malignancies in 
patients treated with oral immunosuppressive drugs are 
derived from transplant patients (9, 10). Immunosuppres-
sive agents may increase the risk of cancer development 
by causing DNA damage and diminishing DNA repair 
mechanisms. Tumour angiogenesis may be promoted and 
the susceptibility to viral infections may be increased. 
Finally, immune surveillance, which normally prevents 
the growth and development of malignancies, may 
be inhibited by immunosuppressive drugs (9, 11, 12). 
Recent studies also report an increased risk of NMSC 
and lymphoma in patients using AZA for autoimmune 
diseases, such as inflammatory bowel disease (IBD) and 
other non-rheumatic autoimmune diseases (13–15).
To date, there has been a lack of data regarding the risk 
of NMSC in patients with AD using oral immunosup-
pressive drugs. 
The aim of this study was to estimate the incidence 
of NMSC in a large cohort of patients with AD treated 
with oral immunosuppressive drugs in the Netherlands 
and to compare these findings with those for the Dutch 
general population. 
MATERIALS AND METHODS
Design
This retrospective cohort study was approved by the Medical 
Ethics Committee of the University Medical Center Utrecht, 
The Netherlands. Data were collected from the Departments of 
Dermatology of the University Medical Center Utrecht and the 
University Medical Center Groningen, The Netherlands, in the 
period from 1989 to 1 January 2014. 
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Study population
All adult patients with AD receiving oral immunosuppressive 
drugs (CsA, AZA, MTX, MMF, EC-MPS and (extended-release) 
tacrolimus) for more than 2 months were included.
For all patients, the follow-up period ended on 1 January 2014, 
independent of whether the treatment had already discontinued. 
AD should have been the primary indication for the treatment 
with oral immunosuppressive drugs. Patients aged < 18 years at 
the start of the treatment were excluded. 
Medical records were screened for the following patient and 
treatment characteristics: sex, age at start of use of oral immuno-
suppressive drug treatment, age at data lock, duration of follow-up 
calculated from the first starting date of oral immunosuppressive 
treatment until data lock, type of medication and cumulative days 
of oral immunosuppressive drug use. 
Outcome
All patient files in the histopathology register (Pathologisch Ana-
tomisch Landelijk Geautomatiseerd Archiefsysteem; PALGA), a 
nationwide database for pathology reports in the Netherlands with 
national coverage, were screened for NMSC until 16 May 2014 
(16). Tumours that developed within 6 months after the start of 
the treatment were considered as not related to drug treatment and 
were excluded from analysis. 
In patients with a diagnosis of NMSC, the following additional 
information was collected: type of malignancy, age at time of 
NMSC diagnosis, cumulative days of oral immunosuppressive 
drug use until diagnosis, time between start of oral immunosup-
pressive drug use and diagnosis, time between cessation of oral 
immunosuppressive drug use and diagnosis, history of UV light 
therapy and history of malignancies before treatment with oral 
immunosuppressive drugs. 
Statistical analysis
All statistical analyses were performed using SPSS statistics 21. 
Subgroup analyses for patients with and without NMSC were 
performed. The Mann–Whitney U test and the χ2 test were used 
to calculate whether there was a statistically significant difference 
between the subgroups in terms of sex, age at data lock, age at 
start of treatment, the total duration of treatment and the duration 
of follow-up. The incidence of NMSC (including both BCC and 
SCC) was compared between patients treated for ≤ 2 years and 
> 2 years and patients treated ≤ 5 years and > 5 years. Separated 
analyzes for the incidence of only SCC were performed as well. 
Dependent on the number of patients treated with monotherapy 
with a specific oral immunosuppressive drug (without a history 
of other oral immunosuppressive drugs), subgroup analyses of the 
individual treatment groups were carried out. 
The standardized incidence ratio (SIR) of SCC in our cohort was 
calculated by dividing the number of observed cases (number of 
newly diagnosed malignancies) by the number of expected cases 
in the general Dutch population in the same period, corrected for 
age (17). The 95% confidence interval (CI) of the SIR was cal-
culated using the indirect method (18). This method was described 
previously by van den Reek et al. (13). Due to the fact that BCCs 
are not systematically registered in the Netherlands, no SIR could 
be determined for BCCs.
RESULTS
Characteristics of the total group
A total of 557 patients with AD (299 male patients, 
53.7%) with one or more treatment episodes with oral 
immunosuppressive drugs from 1 January 1989 until 1 
January 2014 were included in this study (Table I). 
CsA was prescribed most frequently (770 episodes), 
followed by EC-MPS (157 episodes), AZA (139 episo-
des), MTX (69 episodes), MMF (15 episodes), tacro-
limus (24 episodes) and extended-release tacrolimus 
(13 episodes). There was a wide variation in treatment 
duration (Fig. 1).
Results from the histopathology database (PALGA)
NMSC during or after oral immunosuppressive treat-
ments was reported in 18 patients (3.2%) (Fig. 2). The 
individual results are shown in Table II.
SCCs after oral immunosuppressive treatment were 
found in 10 patients (1.8%). Two of these patients had 
more than 1 SCC and 3 of these patients were already 
diagnosed with an SCC before the start of oral immu-
nosuppressive treatment. One of the 10 patients also 
developed a BCC. 
BCCs after oral immunosuppressive treatment were 
found in 9 patients (1.6%). One of these patients also 
developed an SCC. One of these 9 patients developed 3 
BCCs and 2 patients were already diagnosed with a BCC 
before the start of oral immunosuppressive treatment. 
Patients with a malignancy vs. patients without a 
malignancy
Patients who developed NMSC were significantly older 
compared with patients without a malignancy at the 
start of therapy (p < 0.001) and at data lock (p < 0.001) 
(Table III). 
Sex, cumulative days of oral immunosuppressive drugs 
use until data lock and duration of follow-up were not 
statistically significantly different between the groups 
(p = 0.42, p = 0.88, and p = 0.34, respectively). There was 
no significant difference in the incidence of NMSC be-
Table I. Patient characteristics 
All patients 
(n = 557)
Patient characteristics
Male, n (%) 299 (53.7)
Age at data lock, median [IQR] 44.7 [33.4–55.2]
Age at inclusiona, median [IQR] 37.1 [25.5–48.7]
Duration of follow-up in yearb, median [IQR] 6.0 [3.0–10.2]
Total patients years of follow-up 3,855.5
Treatment characteristics
Cyclosporine A only, n (%) 281 (50.4) 
Azathioprine only, n (%) 13 (2.3) 
Enteric-coated mycophenolate sodium only, n (%) 8 (1.4) 
Methotrexate only, n (%) 15 (2.7) 
  >1 oral immunosuppressive drug, n (%) 240 (43.1) 
2 different drugs, n (%) 164 (29.4)
3 different drugs, n (%) 55 (9.9)
4 different drugs, n (%) 20 (3.6)
5 different drugs, n (%) 1 (0.2)
aAge at start of treatment with oral immunosuppressive drugs. bFrom start of oral 
immunosuppressive drugs until data lock.
IQR: interquartile range.
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Fig. 1. Duration of treatment with oral immunosuppressive drugs 
(n = 557).
Table II. Characteristics of patients with non-melanoma skin cancer
Pat. 
No. Sex Tumour Treatment
Age at diagnosis, 
years 
Cumulative 
days of oral 
immunosuppressive 
drug use from start 
until diagnosis
Time between 
start of oral 
immuno-
suppressive 
drug use and 
diagnosis 
(days)
Time between 
stop of oral 
immuno-
suppressive 
drug use and 
diagnosis 
(days)
History of 
UV light 
therapy History of malignancy
1 F SCC CsA 51 554 3,961 < 3,407a Unknown No
2 F SCC CsA 55 227 3,278 3,051 No No
3 F SCC CsA 56 489 808 319 Unknown No
4 M SCC AZA 40 185 185 Still on 
treatment at 
diagnosis
No SCC, dysplastic 
papilloma frenulum, 
non-Hodgkin’s 
lymphoma
5 F SCC (5×) CsA 68 (SCC 1)
69 (SCC 2 and 3)
70 (SCC 4 and 5)
344 (SCC 1)
370 (SCC 2)
441 (SCC 3,4 and 5)
3,380 (SCC 1)
3,644 (SCC 2)
3,715 (SCC 3)
4,038 (SCC 4)
4,101 (SCC 5)
Still on 
treatment at 
diagnosis (SCC 
1 and 2)
62 (SCC 3)
385 (SCC 4)
448 (SCC 5)
Unknown No
6 M SCC EC-MPS, CsA 68 2,705 4,855 1331 UVB SCC
7 M SCC CsA 48 2,166 6,286 4,120 UVB and 
PUVA
No
8 M SCC (2×) CsA 64 (SCC 1 and 2) 632 (SCC 1 and 2) 2,792 (SCC 1)
2,957 (SCC 2)
1,267 (SCC 1)
1,432 (SCC 2)
UVB No
9 F SCC MTX, CsA 59 385 406 Still on 
treatment at 
diagnosis
UVB No
10 F SCC and 
BCC
MTX, CsA 70 (SCC and BCC) 249 (SCC)
452 (BCC)
328 (SCC)
528 (BCC)
Still on 
treatment at 
diagnosis (SCC 
and BCC)
No SCC, breast cancer
11 M BCC CsA 44 210 1,460 < 1,250a PUVA No
12 M BCC CsA 59 281 3,094 2,813 No No
13 F BCC CsA, EC-MPS 31 243 1,574 1,331 UVB No
14 F BCC CsA, MMF, EC-
MPS, Advagraf 
(tacrolimus)
65 437 611 Still on 
treatment at 
diagnosis
UVB No
15 M BCC CsA 66 280 280 Still on 
treatment at 
diagnosis
No BCC
16 F BCC CsA 41 259 350 61 UVB No
17 F BCC (3×) AZA, CsA, MTX 72 (BCC 1, 2 and 3) 462 (BCC 1)
560 (BCC 2 and 3)
462 (BCC 1)
560 (BCC 2 
and 3)
Still on 
treatment at 
diagnosis
UVB No
18 M BCC CsA 74 218 1,128 910 UVB and 
PUVA
8× BCC, SCC, 
adenocarcinoma 
oesophagus
aLoss to follow-up.
AZA: azathioprine; BCC: basal cell carcinoma; CsA: cyclosporin A; EC-MPS: enteric-coated mycophenolate sodium; MMF: mycophenolate mofetil; NMSC: non-melanoma 
skin cancer; PUVA: psoralen and ultraviolet A; SCC: squamous cell carcinoma; UVA: ultraviolet A; UVB: ultraviolet B; UV: ultraviolet.
Fig. 2. Study flow-chart. BCC: basal cell carcinoma; NMSC: non-melanoma 
skin cancer; SCC: squamous cell carcinoma. *Some patients had more 
than one malignancy.
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tween patients treated ≤ 2 years (n = 352, incidence 3.4%) 
and patients treated > 2 years (n = 205, incidence 2.9%) 
(p = 0.76) and no significant difference between patients 
treated ≤ 5 years (n = 482, incidence 3.3%) and patients 
treated > 5 years (n = 75, incidence 2.7%) (p = 0.77).
Patients who developed an SCC were compared with 
those who did not develop an SCC (Table III). Patients 
developing an SCC were significantly older at data lock 
and start of treatment compared with those who did not 
develop an SCC (p = 0.001 and p = 0.004, respectively). 
Sex, cumulative days of oral immunosuppressive drugs 
until data lock and duration of follow-up were not 
statistically significantly different between the groups 
(p = 0.38, p = 0.35, and p = 0.09, respectively). There 
was no significant difference in the incidence of SCC 
between patients treated ≤ 2 years (n = 352, incidence 
2.0%) and those treated > 2 years (n = 205, incidence 
1.5%) (p = 0.65) and no significant difference between 
patients treated ≤  5 years (n = 482, incidence 1.7%) and 
those treated > 5 years (n = 75, incidence 2.7%) (p = 0.54).
Due to the small number of events multivariate ana-
lysis to evaluate the effect of multiple influences on the 
risk of development of NMSC could not be performed.
Subgroup analysis: CsA monotherapy
CsA monotherapy was used in 281 patients (Table IV). 
Patients with CsA monotherapy who developed NMSC 
were statistically significantly older at the start of therapy 
(p = 0.001) and at data lock (p < 0.001) compared with 
patients with CsA monotherapy without malignancy. 
Sex, cumulative days of oral immunosuppressive drugs 
until data lock and duration of follow-up were not statisti-
cally significantly different between the groups (p = 0.96, 
p = 0.79, and p = 0.10, respectively).
Patients with CsA monotherapy who developed SCC 
were compared with patients who did not develop SCC 
(Table IV). Patients developing SCC were significantly 
older at data lock and start of treatment compared with 
patients who did not develop SCC (p = 0.003 and p = 0.02, 
respectively). Duration of follow-up was longer in pa-
tients who developed an SCC (p = 0.01) vs. patients who 
did not develop an SCC. Sex and the cumulative days 
of oral immunosuppressive drugs until data lock were 
not significantly different (p = 0.31 and p = 0.30) between 
patients with and without an SCC. 
Subgroup analyses of the other treatment groups were 
not performed due to the small number of patients in 
these groups.
Comparison with the Dutch population
The SIR for the risk of development of an SCC in this 
study population was 13.1 (95% CI 6.5–19.7). One 
patient developed 5 SCCs; thereby increasing the SIR 
value. The calculated SIR for the development of an 
SCC, without this outlier, was 8.8 (95% CI 3.4–14.3). 
In addition, 3 of the 10 patients already had a SCC 
before the start of treatment and probably were more 
prone to develop another SCC. The calculated SIR for 
the development of an SCC, without these 3 patients, 
was 10.7 (95% 4.6–16.7). 
The SIR for the risk of development of an SCC in 
patients with CsA monotherapy was 25.3 (95% CI 
10.3–40.2). The calculated SIR for the development 
of SCC in patients with CsA monotherapy, without the 
Table III. Patient characteristics of the total group (n = 557). Non melanoma skin cancer (NMSC) and specified for squamous cell carcinoma (SCC)
NMSC during or 
after treatment 
(n = 18)
No NMSC during 
or after treatment 
(n = 539)
p-value 
differences
SCC during or 
after treatment 
(n = 10)
No SCC during or 
after treatment 
(n = 547)
p-value 
differences
Male, n (%) 8 (44.4%) 291 (54.0%) 0.424 4 (40.0) 295 (53.9) 0.381
Age at data lock, years, median [IQR] 61.8 [51.7–70.5] 44.1 [32.7–53.8] < 0.001 61.2 [52.2–70.5] 44.3 [33.0–54.7] 0.001
Age at start, years, median [IQR]a 54.7 [40.4–64.2] 36.4 [25.0–48.1] < 0.001 54.7 [40.5–58.3] 36.9 [25.1–48.3] 0.004
Cumulative days of oral immunosuppressive drug 
use until last day of follow-up, median [IQR]
499.0 [255.0–
1,087.0]
505.0 [252.0–
1,123.0]
0.879 531.5 [438.3–
1,663.5]
498.0 [252.0–
1,117.0]
0.351
Durations of follow-up, years, median [IQR]b 6.9 [3.9–12.5] 6.0 [2.9–10.1] 0.343 11.7 [4.6–13.3] 6.0 [2.9–10.1] 0.087
aAge at start of treatment with oral immunosuppressive drugs. bFrom start of oral immunosuppressive drugs until data lock.
IQR: interquartile range; NMSC: non-melanoma skin cancer; SCC: squamous cell carcinoma.
Table IV. Patient characteristics of cyclosporine A (CsA) monotherapy (n = 281). Non melanoma skin cancer (NMSC) and specified for squamous 
cell carcinoma (SCC)
CsA monotherapy 
with NMSC during 
or after treatment
(n = 11)
CsA monotherapy 
without NMSC during 
or after treatment
(n = 270)
p-value 
differences
CsA monotherapy 
with SCC during 
or after treatment 
(n = 6)
CsA monotherapy 
without SCC during 
or after treatment 
(n = 275)
p-value 
differences
Male, n (%) 6 (54.5%) 145 (53.7 %) 0.956 2 (33.3) 149 (54.2) 0.311
Age at data lock, years, median [IQR] 59.0 [52.3–69.5] 40.1 [28.8–51.0] < 0.001 58.7 [52.2–68.8] 40.3 [29.1–51.8] 0.003
Age at start, years, median [IQR]a 51.0 [40.2–59.7] 32.1 [23.6–45.1] 0.001 50.3 [38.3–57.5] 32.4 [23.7–45.3] 0.022
Cumulative days of oral immunosuppressive 
use until last day of follow-up, median [IQR]
379.0 [227.0–632.0] 350.5 [210.8–772.3] 0.785 521.5 [341.0–
1015.5]
345.0 [212.0–765.0] 0.304
Durations of follow-up, years, median [IQR]b 11.0 [4.0–12.5] 5.4 [2.5–9.7] 0.095 12.5 [9.3–14.0] 5.3 [2.6–9.7] 0.012
aAge at moment of start of treatment with oral immunosuppressive drugs. bFrom start of oral immunosuppressive drugs until data lock. 
IQR: interquartile range; NMSC: non-melanoma skin cancer.
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aforementioned outlier who developed 5 SCCs, was 14.3 
(95% CI 2.9–25.7).
DISCUSSION
This is the first study investigating the occurrence of 
NMSC in a large group of patients with AD treated 
with oral immunosuppressive drugs. NMSC during or 
after oral immunosuppressive treatments were reported 
in 18 out of 557 patients (3.2%). The patients who de-
veloped NMSC were significantly older than those who 
did not develop these malignancies. Follow-up did not 
differ significantly between these groups. However, it 
is noteworthy that in 4 out of the 18 patients the malig-
nancy was detected under the age of 45 years, which is 
relatively young. 
Literature concerning the risk of developing NMSC 
during or after oral immunosuppressive treatment in 
patients with AD are scarce. In a retrospective cohort 
study, Väkevä et al. (19) evaluated 272 patients with 
various skin diseases treated with CsA, with a median 
follow-up time of 10.9 years. No NMSC or lymphoma 
was found in the patients with AD. Berth-Jones et al. (20) 
evaluated the use of CsA in 100 patients with AD (mean 
follow-up time 8 weeks). They reported one BCC, which 
developed in a sebaceous naevus; no SCC was reported. 
Furthermore, there are some case reports describing 
(cutaneous) lymphoma in patients with AD using oral 
immunosuppressive drugs (21–23).
Most information on the development of NMSC after 
oral immunosuppressive treatment is derived from or-
gan transplant studies. These patients have a markedly 
increased risk of NMSC (12, 24). The cumulative inci-
dence of malignancies is reported to increase in relation 
to the number of  years since transplantation (25). A 
mean interval between transplantation and tumour di-
agnosis is reported in the literature: 8 years for patients 
who receive transplants at approximately 40 years of 
age and approximately 3 years for those who receive 
transplants after the age of 60 years (24, 26, 27). These 
results are not entirely applicable to patients with AD, 
because organ transplant patients often use more than 
one oral immunosuppressive drug simultaneously and 
they more often have prolonged treatment, resulting in 
more long-term data. 
More recently, data relating oral immunosuppressive 
treatment to the risk of developing malignancies in other 
chronic inflammatory diseases have become available. 
Lymphomas are reported in patients with rheumatoid 
arthritis treated with methotrexate (28, 29). In patients 
with IBD, various studies have shown that patients trea-
ted with thiopurines had an increased risk of development 
of NMSC or lymphoproliferative disorders (30–32). In 
patients with psoriasis, different studies have shown 
an increased risk of NMSC (33–35). However, most of 
these patients were also treated with UV light for longer 
periods, which might have made a major contribution to 
the increased risk of SCC.
Since AD and NMSC are both common diseases, it can 
be expected that patients with AD will develop NMSC, 
irrespective of the immunosuppressive treatment. Con-
founding factors, such as other therapeutic interventions, 
lifestyle factors and occupation (indoors or outdoors) are 
difficult to eliminate and causal relationships are difficult 
to affirm. Two meta-analyses were found in literature. 
Deckert et al. (36) included 6 systematic reviews on the 
risk of cancer in patients with AD. They concluded that 
there are no data suggesting that AD itself is associated 
with an increased risk of NMSC. A more recent meta-
analysis performed by Gandini et al. (37) included 18 
studies (9 on NMSC). They concluded that patients with 
AD may be at increased risk of BCC, but methodological 
limitations prevented them from drawing a definitive 
conclusion. 
In the present study, we compared our data concerning 
SCC with the general Dutch population with a correction 
for age and found an increased SIR for development of 
an SCC. These findings were corrected for external, time-
dependent influences, by comparing our patients with a 
patient cohort of the same age in the same time period. 
The SIR for the risk of development of SCC in the pa-
tients included in this study was 13.1 (95% CI 6.5–19.7) 
(8.8 without outlier with 5 SCCs). Earlier studies in organ 
transplantation (2,561 patients) and autoimmune hepatitis 
(45 patients) reported an SIR of 65 (95% CI 53–79) and 
28.5 (95% CI 9.9–43.1), respectively (38, 39).
The SIR of 13.1 suggests that patients with AD trea-
ted with oral immunosuppressive drugs are at risk of 
developing an SCC. For interpretation of the results it 
is important to realize that the numbers of SCCs were 
low. No significant association was found between the 
cumulative days of treatment and the risk of develop-
ment of SCC (p = 0.35). In a recent study investigating 
the incidence of SCC in 59 patients with auto-immune 
inflammatory rheumatic diseases treated with AZA, a 
higher cumulative dose and a treatment duration of at 
least 11 years were qualified as risk factors for the deve-
lopment of SCC (13). In our study only 16 patients had 
a treatment duration of > 10 years. None of the patients 
developed an SCC. In addition, no significant differen-
ces were seen in the SCC incidence between patients 
treated ≤ 5 years and patients treated > 5 years with oral 
immunosuppressive drugs.
For dermatologists prescribing oral immunosuppres-
sive drugs in daily practice, it is important to know the 
risk of developing NMSC in individual drugs. A sub-
group analysis in our study was only possible for CsA. 
The SIR for 281 patients treated with CsA monotherapy 
for development of an SCC was 25.3 (95% CI 10.3–40.2), 
suggesting an increased risk of developing an SCC during 
or after CsA treatment. However, one patient developed 5 
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SCCs; thereby exerting much influence on the SIR value. 
The calculated SIR for the development of SCC, without 
this outlier, was 14.3 (95% CI 2.9–25.7).
Also in this group, lack of association with treatment 
duration and the sometimes long intervals between CsA 
discontinuation and the development of an SCC makes 
the relationship doubtful in some patients. 
For interpretation of the results it is important to realize 
that 5 out of 18 patients with NMSC during or after oral 
immunosuppressive treatment had a previous similar type 
of tumour before the start of treatment. These patients 
are probably more prone to develop the tumour; it is 
not clear what the contribution of the immunosuppres-
sive treatment was to the development of new tumours. 
Robsahm et al. (40) showed that patients with a history 
of SCC were more at risk of developing another SCC 
(SIR of 9.88 in women and 10.1 in men). In our study, the 
calculated SIR for the development of an SCC, without 
these 3 patients who had already had an SCC, was 10.7 
(95% CI 4.6–16.7).
Study limitations
The median duration of follow-up in this study was 6.0 
years (IQR 3.0–10.2), which is relatively short. However, 
the incidence of NMSC was comparable in the patients 
with follow-up ≤5 years (n = 245) compared with the gro-
up with a follow-up >5 years (n = 312) (data not shown).
Data concerning BCCs were collected with utmost 
care, but there will probably be an underestimation of 
the real incidence. This might be attributed to the fact 
that BCCs are regularly treated without histological 
confirmation. 
Data on a history of UV light therapy were not avail-
able for all evaluated patients, thus the influence of UV 
light therapy on the development of NMSC is unclear. 
However, it is common in the Netherlands to prescribe 
UV light therapy only in short courses of up to 4 months. 
Psoralen combined with UV A light (PUVA), which is 
associated with NMSC, is rarely prescribed in patients 
with AD in the Netherlands. In addition, data on skin 
type, phototype, naevi, hair and eye colour and history 
of sunburns were lacking. Data on tumour aggressivity 
were not available. 
Finally, the data for the general population that were 
used to calculate the SIR for SCC matched our cohort 
on age and calendar year, but not on sex. 
Conclusion
NMSC during or after long-term treatment with oral 
immunosuppressive drugs was found in 18 out of 557 
(3.2%) patients with AD, with an SIR of 13.1 for SCC. 
For interpretation of the results it is important to include 
other factors: in this study we found a lack of association 
between treatment duration and the risk of developing a 
tumour, a history of a malignancy before treatment in 5 
out of 18 patients, and a long interval between treatment 
discontinuation and the development of the tumour in 
some patients. 
It is always important to balance the benefit of treat-
ment against the potential risks in each individual patient. 
Patients treated with oral immunosuppressive drugs 
should regularly visit the dermatologist for monitoring 
treatment effect and safety laboratory tests. Thorough 
inspection of the skin during each visit enables early 
detection and treatment of NMSC. As the occurrence of 
NMSC in our study was independent of treatment dura-
tion, skin inspection should start within the first year 
during treatment.
ACKNOWLEDGEMENTS
The authors would like to thank Andrew Walker for proofreading 
the manuscript. 
The authors declare no conflicts of interest.
REFERENCES
1. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, 
Gelmetti C, et al. Guidelines for treatment of atopic eczema 
(atopic dermatitis) part I. J Eur Acad Dermatol Venereol 
2012; 26: 1045–1060.
2. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. 
Efficacy and safety of systemic treatments for moderate-
to-severe atopic dermatitis: a systematic review. J Allergy 
Clin Immunol 2014; 133: 429–438.
3. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Wel-
ler MS, Bruijnzeel-Koomen CA. Enteric-coated myco phenolate 
sodium versus cyclosporin A as long-term treatment in 
adult patients with severe atopic dermatitis: a randomized 
controlled trial. J Am Acad Dermatol 2011; 64: 1074–1084.
4. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, 
Spuls PI. A randomized trial of methotrexate versus aza-
thioprine for severe atopic eczema. J Allergy Clin Immunol 
2011; 128: 353–359.
5. Schmitt J, Schäkel K, Fölster-Holst R, Bauer A, Oertel R, Au-
gustin M, et al. Prednisolone vs. ciclosporin for severe adult 
eczema. An investigator-initiated double-blind placebo-con-
trolled multicenter trial. Br J Dermatol 2010; 162: 661–668.
6. Van der Schaft J, Politiek K, van den Reek JM, Kievit W, de 
Jong EM, Bruijnzeel-Koomen CA, et al. Drug survival for 
azathioprine and enteric-coated mycophenolate sodium in a 
long-term daily practice cohort of adult patients with atopic 
dermatitis. Br J Dermatol 2016; 175: 199–202. 
7. Politiek K, van der Schaft J, Coenraads PJ, de Bruin-Weller 
MS, Schuttelaar ML. Drug survival for methotrexate in a 
daily practice cohort of adult patients with severe atopic 
dermatitis. Br J Dermatol 2016; 174: 201–203. 
8. Van der Schaft J, Politiek K, van den Reek JM, Christoffers 
WA, Kievit W, de Jong EM, et al. Drug survival for ciclosporin 
A in a long-term daily practice cohort of adult patients with 
atopic dermatitis. Br J Dermatol 2015; 172: 1621–1627. 
9. Demir T, Ozel L, Gökçe AM, Ata P, Kara M, Eriş C, et al. 
Cancer screening of renal transplant patients undergoing 
long-term immunosuppressive therapy. Transplant Proc 
2015; 47: 1413–1417.
10. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors 
after solid organ transplantation. Int J Cancer 2009; 125: 
1747–1754.
11. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after 
kidney transplantation in the United States. Am J Transplant 
2004; 4: 905–913.
12. Geissler EK. Post-transplantation malignancies: here today, 
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
F. M. Garritsen et al.730
www.medicaljournals.se/acta
gone tomorrow? Nat Rev Clin Oncol 2015; 12: 705–717. 
13. Van den Reek JM, van Lümig PP, Janssen M, Schers HJ, 
Hendriks JC, van de Kerkhof PC, et al. Increased incidence 
of squamous cell carcinoma of the skin after long-term 
treatment with azathioprine in patients with auto-immune 
inflammatory rheumatic disease. J Eur Acad Dermatol Ve-
nereol 2014; 28: 27–33. 
14. Khan N, Abbas AM, Lichtenstein GR, Loftus EV Jr, Bazzano LA. 
Risk of lymphoma in patients with ulcerative colitis treated 
with thiopurines: a nationwide retrospective cohort study. 
Gastroenterology 2013; 145: 1007–1015. 
15. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, 
Hift R. Use of thiopurines in the treatment of inflammatory 
bowel disease is associated with an increased risk of non-
melanoma skin cancer in an at-risk population: a cohort 
study. J Gastroenterol Hepatol 2012; 27: 385–389. 
16. Public pathology database. [cited 2016 August 19]. Available 
from: http: //www.palga.nl/en/.
17. Comprehensive Cancer Centre the Netherlands. [cited 2016 
July 22]. Available from: http: //www.cijfersoverkanker.nl. 
18. Boyle P, Parkin DM. Statistical methods for registries. [cited 
2016 April 29]. Available from: http: //www.iarc.fr/en/pu-
blications/pdfs-online/epi/sp95/sp95-chap11.pdf.
19. Väkevä L, Reitamo S, Pukkula E, Sarna S, Ranki A. Long-term 
follow-up of cancer risk in patients treated with short-term 
cyclosporine. Acta Derm Venereol 2008; 88: 117–120. 
20. Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, Eng-
lish JS, Freeman K, et al. Long-term efficacy and safety of 
cyclosporin in severe adult atopic dermatitis. Br J Dermatol 
1997; 136: 76–81. 
21. Sinha A, Velangi S, Natarajan S. Non-Hodgkin’s lymphoma 
following treatment of atopic eczema with cyclosporin A. 
Acta Derm Venereol 2004; 84: 327–328.
22. Nakamura S, Takeda K, Hashimoto Y, Mizumoto T, Ishida-
Yamamoto A, Iizuka H. Primary cutaneous CD30+ lymp-
hoproliferative disorder in an atopic dermatitis patient on 
cyclosporine therapy. Indian J Dermatol Venereol Leprol 
2011; 77: 253. 
23. Mougel F, Dalle S, Balme B, Houot R, Thomas L. Aggressive 
CD30 large cell lymphoma after cyclosporine given for pu-
tative atopic dermatitis. Dermatology 2006; 213: 239–241. 
24. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ 
transplantation. N Engl J Med 2003; 348: 1681–1691. 
25. Wisgerhof HC, van der Geest LG, de Fijter JW, Haasnoot GW, 
Claas FH, le Cessie S, et al. Incidence of cancer in kidney-
transplant recipients: a long-term cohort study in a single 
center. Cancer Epidemiol 2011; 35: 105–111. 
26. Euvrard S, Kanitakis J, Pouteil-Noble C, Dureau G, Touraine 
JL, Faure M, et al. Comparative epidemiologic study of prema-
lignant and malignant epithelial cutaneous lesions developing 
after kidney and heart transplantation. J Am Acad Dermatol 
1995; 33: 222–229.
27. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tu-
mours posttransplantation: a retrospective analysis of 28 
years’ experience at a single centre. Transplant Proc 1997; 
29: 828–830.
28. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud 
N, Sibilia J, et al. Lymphomas in rheumatoid arthritis patients 
treated with methotrexate: a 3-year prospective study in 
France. Blood 2002; 99: 3909–3915. 
29. Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles 
G, Hall S, et al. Incidence of melanoma and other malig-
nancies among rheumatoid arthritis patients treated with 
methotrexate. Arthritis Rheum 2008; 59: 794–799.
30. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, 
Chevaux JB, Simon T, et al. Increased risk for nonmela-
noma skin cancers in patients who receive thiopurines for 
inflammatory bowel disease. Gastroenterology 2011; 141: 
1621–1628.
31. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann 
M, Cosnes J, et al. Lymphoproliferative disorders in patients 
receiving thiopurines for inflammatory bowel disease: a 
prospective observational cohort study. Lancet 2009; 374: 
1617–1625.
32. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. 
Increased risk of lymphoma among inflammatory bowel 
disease patients treated with azathioprine and 6-mercapto-
purine. Gut 2005; 54: 1121–1125.
33. Paul CF, Ho VC, McGeown G, Christophers E, Schmidtmann 
B, Guillaume JC, et al. Risk of malignancies in psoriasis pa-
tients treated with cyclosporine: a 5 y cohort study. J Invest 
Dermatol 2003; 120: 211–216. 
34. Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, 
Richard MA, et al. Risk of cancer in psoriasis: a systematic 
review and meta-analysis of epidemiological studies. J Eur 
Acad Dermatol Venereol 2013; 27 suppl 3: 36–46. 
35. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. 
The risk of cancer in patients with psoriasis: a population 
based cohort study in the health improvement network. JAMA 
Dermatol 2016; 152: 282–290.
36. Deckert S, Kopkow C, Schmitt J. Nonallergic comorbidities 
of atopic eczema: an overview of systemic reviews. Allergy 
2014; 69: 37–45.
37. Gandini S, Stanganelli I, Palli D, De Giorgi V, Masala G, Caini 
S. Atopic dermatitis, naevi count and skin cancer risk: a 
meta-analysis. J Dermatol Sci 2016; 84: 137–143.
38. Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O, 
et al. Skin cancer in kidney and heart transplant recipients 
and different long-term immunosuppressive therapy regi-
mens. J Am Acad Dermatol 1999; 40: 177–186.
39. Leung J, Dowling L, Obadan I, Davis J, Bonis PA, Kaplan MM, 
et al. Risk of non-melanoma skin cancer in autoimmune 
hepatitis. Dig Dis Sci 2010; 55: 3218–3223.
40. Robsahm TE, Karagas MR, Rees JR, Syse A. New malignancies 
after squamous cell carcinoma and melanomas: a population-
based study from Norway. BMC Cancer 2014; 14: 210.
